Caerus Molecular Diagnostics is categorized under Commercial Biotechnical Research in Mountain View, CA and active since 2011.
Caerus Molecular Diagnostics was established in 2011, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 6215120 by the NAICS.
If you are seeking more information, feel free to contact at the company’s single location by writing to 465 Fairchild Drive, Mountain View, California CA 94043 or by phoning (650) 967-3228. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Caerus Molecular Diagnostics |
| Address: | 465 Fairchild Drive, Mountain View, California 94043 |
| Phone Number: | (650) 967-3228 |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 6215120 |
| Share This Business: |
Caerus Molecular Diagnostics was started in 2011 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 6215120. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact for inquiries that concern Caerus Molecular Diagnostics by calling the company number (650) 967-3228, as your correspondence is most welcome. Additionally, the physical location of the single location of Caerus Molecular Diagnostics can be found at the coordinates 37.40333,-122.05184 as well as the street address 465 Fairchild Drive in Mountain View, California 94043.
For its online presence, you may visit Caerus Molecular Diagnostics’s website at and engage with its social media outlets through on Twitter and on Facebook.